We are live on ! Find out more
REPL icon

Replimune Group

106 hedge funds and large institutions have $704M invested in Replimune Group in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 26

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

4% more funds holding

Funds holding: 102106 (+4)

1.15% more ownership

Funds ownership: 81.52%82.66% (+1.1%)

1% more capital invested

Capital invested by funds: $696M → $704M (+$7.51M)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
106
Holders Change
+4
Holders Change %
+3.92%
% of All Funds
1.83%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
12
Increased
48
Reduced
26
Closed
8
Calls
$2.75M
Puts
Net Calls
+$2.75M
Net Calls Change
+$417K
Name Holding Trade Value Shares
Change
Change in
Stake
OFM
1
Omega Fund Management
Massachusetts
$74.1M -$7.35M -385,226 -8%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$72M -$32.6M -1,711,360 -29%
BBA
3
Baker Bros. Advisors
New York
$67.2M +$5.77M +302,762 +8%
RG
4
Redmile Group
California
$63M
AVLSA
5
Atlas Venture Life Science Advisors
Massachusetts
$53.7M -$1.93M -101,327 -3%
BlackRock
6
BlackRock
New York
$47.8M +$8.43M +442,331 +19%
Vanguard Group
7
Vanguard Group
Pennsylvania
$31.9M +$1.71M +89,618 +5%
State Street
8
State Street
Massachusetts
$25.1M -$3.81M -199,979 -12%
T. Rowe Price Investment Management
9
T. Rowe Price Investment Management
Maryland
$21.2M +$23.4M +1,226,870 New
EA
10
Emerald Advisers
Pennsylvania
$19.6M +$825K +43,263 +4%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$18.9M +$48.5K +2,543 +0.2%
EMFAT
12
Emerald Mutual Fund Advisers Trust
Pennsylvania
$16.7M -$388K -20,332 -2%
BI
13
BVF Inc
California
$16M
AG
14
Artal Group
Luxembourg
$15.5M
FLSM
15
Frazier Life Sciences Management
California
$13.9M
Geode Capital Management
16
Geode Capital Management
Massachusetts
$11.8M +$2.75M +144,297 +27%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$11.2M +$3.32M +174,300 +37%
Citadel Advisors
18
Citadel Advisors
Florida
$11.2M +$1.2M +62,706 +11%
CS
19
Candriam SCA
Luxembourg
$10.5M +$2.23M +117,068 +24%
Morgan Stanley
20
Morgan Stanley
New York
$9.65M -$904K -47,389 -8%
GPP
21
Great Point Partners
Connecticut
$6.74M +$7.44M +390,000 New
Northern Trust
22
Northern Trust
Illinois
$6.64M +$1.36M +71,086 +23%
Amundi
23
Amundi
France
$6.44M -$171K -8,952 -2%
Schroder Investment Management Group
24
Schroder Investment Management Group
United Kingdom
$5.97M +$180K +9,438 +3%
Charles Schwab
25
Charles Schwab
California
$4.36M +$807K +42,307 +20%

REPL Hedge Fund Activity: Q3 2022 in Review

106 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q3 2022, worth a combined $704M — up 1.1% from $696M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new REPL positions and 8 closed out — a net gain of 4 holders — while 48 added to existing stakes and 26 trimmed.

The largest buyer was BlackRock, adding an estimated $8.43M. The largest seller was T. Rowe Price Associates, cutting an estimated $32.6M.

  • 106 institutional investors held Replimune Group (REPL) as of Q3 2022, up from 102 in Q2 2022.
  • Funds reported $704M of Replimune Group stock for Q3 2022, up 1.1% quarter-over-quarter.
  • 12 funds opened new Replimune Group positions in Q3 2022 and 8 closed out, a net change of +4 holders.
  • The largest Replimune Group buyer in Q3 2022 was BlackRock, an estimated $8.43M added.
  • The largest Replimune Group seller in Q3 2022 was T. Rowe Price Associates, an estimated $32.6M sold.

Based on aggregated 13F filings for Q3 2022.